WO2025248464 - LOOP REINFORCEMENT EXPRESSION SYSTEM FOR IMPROVED CELL THERAPY PRODUCTS
National phase entry is expected:
Publication Number
WO/2025/248464
Publication Date
04.12.2025
International Application No.
PCT/IB2025/055514
International Filing Date
28.05.2025
Title **
[English]
LOOP REINFORCEMENT EXPRESSION SYSTEM FOR IMPROVED CELL THERAPY PRODUCTS
[French]
SYSTÈME D'EXPRESSION DE RENFORCEMENT EN BOUCLE POUR PRODUITS DE THÉRAPIE CELLULAIRE AMÉLIORÉS
Applicants **
CELL CONTROL BIOTHERAPEUTICS, INC.
Inventors
SAHILLIOGLU, Ali Can
OZDESLIK SAHILLIOGLU, Rana Nur
Priority Data
2037809
29.05.2024
NL
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3008 | |
| EPO | Filing, Examination, Granting | 16167 | |
| Japan | Filing, Examination, Granting | 2493 | |
| South Korea | Filing, Examination, Granting | 2756 | |
| USA | Filing, Examination, Granting | 6390 |
Total:
30,814
Contact Us
Abstract[English]
This invention pertains in general to, for example, T cell and NK cells for use as cell therapy products, for example in the treatment of a tumor in a patient suffering from cancer. The invention provides heterologous nucleic acids encoding cell surface expressed antigen receptors under the control of a promoter that is induced when the antigen receptor is activated, for example upon interaction between the antigen receptor and its cognate binding partner (antigen) expressed on a (tumor) cell.[French]
La présente invention concerne de manière générale, par exemple, des cellules T et des cellules NK destinées à être utilisées en tant que produits de thérapie cellulaire, par exemple dans le traitement d'une tumeur chez un patient souffrant d'un cancer. L'invention concerne des acides nucléiques hétérologues codant pour des récepteurs antigéniques exprimés en surface cellulaire sous le contrôle d'un promoteur qui est induit lorsque le récepteur antigénique est activé, par exemple lors de l'interaction entre le récepteur antigénique et son partenaire de liaison parent (antigène) exprimé sur une cellule (tumorale).